Literature DB >> 8758639

Pediatric cholesteatoma: an individualized, single-stage approach.

S C Parisier1, M B Hanson, J C Han, A J Cohen, B A Selkin.   

Abstract

We report our experience with a one-stage surgery for pediatric cholesteatoma in 216 ears. Our technique is based on three main principles: (1) the surgery is individualized; (2) the goal of surgery is to completely remove cholesteatoma and related disease in one operation; and (3) the reconstruction is performed to provide both good hearing and a dry, trouble-free ear. The incidence of recidivism was 10.2%, and the rate achieved was 13.3% at 5 years and 24% at 10 years. Canal wall down surgery was the predominant procedure used. The incidence of intraoperative neurosensory hearing loss, vertigo, and facial nerve injury was extremely low. The postoperative cavity problems encountered were minimal.

Entities:  

Mesh:

Year:  1996        PMID: 8758639     DOI: 10.1016/S0194-5998(96)70145-6

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Comparison of echo-planar diffusion-weighted imaging and delayed postcontrast T1-weighted MR imaging for the detection of residual cholesteatoma.

Authors:  F Venail; A Bonafe; V Poirrier; M Mondain; A Uziel
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-16       Impact factor: 3.825

Review 2.  A review of current progress in acquired cholesteatoma management.

Authors:  Chin-Lung Kuo; Wen-Huei Liao; An-Suey Shiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-17       Impact factor: 2.503

3.  Trends and Healthcare Use Following Different Cholesteatoma Surgery Types in a National Cohort, 2003-2019.

Authors:  Zhen Jason Qian; Emma D Tran; Jennifer C Alyono; Alan G Cheng; Iram N Ahmad; Kay W Chang
Journal:  Otol Neurotol       Date:  2021-10-01       Impact factor: 2.619

4.  Analysis of long-term anatomic results of radical mastoidectomy.

Authors:  Horia Mocanu; Adela-Ioana Mocanu; Gabriella Coadă; Alexandru Bonciu; Mihai-Adrian Schipor; Marian Rădulescu
Journal:  Exp Ther Med       Date:  2021-12-17       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.